Jul 27, 2025, 16:39

2025 ONC US PARPi mCRPC IME Grant

Request for proposals to support independent medical education on PARP-Inhibitor combination treatments in metastatic castration-resistant prostate cancer (mCRPC), focusing on biomarker testing, safety, efficacy, and guideline-concordant care in a rapidly evolving clinical landscape.

Eligibility Criteria:

Applicant organizations must be based in the United States.
Eligible entities include medical, nursing, allied health, or pharmacy professional schools; healthcare institutions (large or small); professional societies; medical education companies; and other organizations whose mission relates to healthcare professional education or improvement.
Individuals or physician-owned private practices are not eligible.
Multi-institutional projects are permitted but all participating organizations must have a defined role, with one organization acting as prime applicant.
For projects offering continuing education credit, the applicant must hold U.S. accreditation.

Funding Details:

Individual projects may request up to $350,000 (includes direct costs plus institutional overhead, capped at 28%).
Total budget available under this RFP is approximately $850,000.
Awarded funds may cover direct educational costs, program development, and capped overhead.
Multi-supported (jointly funded) educational programs are encouraged.

Deadline:

Grant applications must be submitted by August 21, 2025 at 23:59 Eastern Time (GMT −5).

Where to Go for Further Information:

Submit via the Pfizer CyberGrants portal.
Select “Start A New Knowledge Gap Application,” choose “Response to a Request for Proposal (RFP),” then “2025 ONC US PARPi mCRPC IME.”
For questions, contact the Grant Officer, Lori Carpenter, at [email protected] (subject line: “2025 ONC US PARPi mCRPC IME”).

biomarker testing cancer clinical education Continuing education guideline-concordant care independent medical education mCRPC metastatic castration-resistant prostate cancer OncoDaily Oncology PARP inhibitors pfizer professional societies prostate cancer US Oncology

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing